On May24, 2016, Dipexium Pharmaceuticals, Inc. (the Company) held its 2016 Annual Meeting of Stockholders (the Annual Meeting). Of the 10,351,613 shares of the Companys common stock outstanding and eligible to vote at the Annual Meeting, 9,909,741 shares, or 95.7% of the eligible common stock, were present either in person or by proxy.The final results of the matters voted on at the Annual Meeting are provided below.

Proposal 1

: The following individuals were elected as directors to hold office for the term that expires at the 2017 Annual Meeting of Stockholders for each director, or until their respective successors are elected and qualified, or until such directors earlier resignation or removal:

DirectorName

For

Withheld

Broker

Non-Votes

Abstained

Robert J. DeLuccia

8,846,874

9,536

1,053,331

0

David P. Luci

8,847,774

8,636

1,053,331

0

Jack H. Dean

7,493,873

1,362,537

1,053,331

0

Michael Duffy

8,847,728

8,682

1,053,331

0

Thomas Harrison

8,847,728

8,682

1,053,331

0

William J. McSherry,Jr.

8,847,728

8,682

1,053,331

0

Barry Kagan

8,847,728

8,682

1,053,331

0

Proposal 2

: To approve and ratify the Companys Second Amended and Restated Bylaws, regarding Delaware law being the exclusive and sole jurisdiction for certain types of litigation.

For:

7,507,219

Against:

1,347,191

Abstained:

2,000

Broker Non-Votes:

1,053,331

Proposal 3

: To amend the Companys Certificate of Incorporation to provide that the Board of Directors are expressly authorized to make, alter, amend or repeal the Bylaws of the Company.

For:

7,505,214

Against:

1,348,876

Abstained:

2,320

Broker Non-Votes:

1,053,331

Proposal 4

: CohnReznick, LLP was ratified as the Companys Independent Registered Public Accounting Firm for the fiscal year ending December31, 2016.

For:

9,894,179

Against:

11,698

Abstained:

3,864

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May26, 2016

DIPEXIUM PHARMACEUTICALS,INC.

By:

/s/ David P. Luci

Name:

David P. Luci

Title:

President and Chief Executive Officer

3

makes a similar move, sign up!

Other recent filings from the company include the following:

Dipexium Pharmaceuticals, Inc. Just Filed Its Quarterly Report: Loss per share Basic... - Nov. 9, 2017
Departure of Directors or Certain - Oct. 27, 2017

Auto Refresh

Feedback